Abstract

BackgroundThe polymorphic nature of many malaria vaccine candidates presents major challenges to achieving highly efficacious vaccines. Presently, there is very little knowledge on the prevalence and patterns of functional immune responses to polymorphic vaccine candidates in populations to guide vaccine design. A leading polymorphic vaccine candidate against blood-stage Plasmodium falciparum is apical membrane antigen 1 (AMA1), which is essential for erythrocyte invasion. The importance of AMA1 as a target of acquired human inhibitory antibodies, their allele specificity and prevalence in populations is unknown, but crucial for vaccine design.MethodsP. falciparum lines expressing different AMA1 alleles were genetically engineered and used to quantify functional antibodies from two malaria-exposed populations of adults and children. The acquisition of AMA1 antibodies was also detected using enzyme-linked immunosorbent assay (ELISA) and competition ELISA (using different AMA1 alleles) from the same populations.ResultsWe found that AMA1 was a major target of naturally acquired invasion-inhibitory antibodies that were highly prevalent in malaria-endemic populations and showed a high degree of allele specificity. Significantly, the prevalence of inhibitory antibodies to different alleles varied substantially within populations and between geographic locations. Inhibitory antibodies to three specific alleles were highly prevalent (FVO and W2mef in Papua New Guinea; FVO and XIE in Kenya), identifying them for potential vaccine inclusion. Measurement of antibodies by standard or competition ELISA was not strongly predictive of allele-specific inhibitory antibodies. The patterns of allele-specific functional antibody responses detected with our novel assays may indicate that acquired immunity is elicited towards serotypes that are prevalent in each geographic location.ConclusionsThese findings provide new insights into the nature and acquisition of functional immunity to a polymorphic vaccine candidate and strategies to quantify functional immunity in populations to guide rational vaccine design.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-016-0691-6) contains supplementary material, which is available to authorized users.

Highlights

  • The polymorphic nature of many malaria vaccine candidates presents major challenges to achieving highly efficacious vaccines

  • A major challenge in the development of highly efficacious vaccines is antigen polymorphism, which is an important issue for many leading vaccine candidates. This includes the RTS,S vaccine, which recently completed phase III trials, and vaccines based on apical membrane antigen 1 (AMA1) and merozoite surface protein 2 (MSP2); for all these candidates, vaccine efficacy against malaria or Plasmodium falciparum infection was higher for episodes caused by vaccine-like strains compared to vaccine-dissimilar strains [1,2,3]

  • Construction and phenotyping of genetically engineered P. falciparum lines We generated P. falciparum isolates from a common parental line (W2Mef ) which were genetically engineered to express one of six different AMA1 alleles that broadly represent the antigenic diversity of AMA1, including alleles from our study population [31, 32]

Read more

Summary

Introduction

The polymorphic nature of many malaria vaccine candidates presents major challenges to achieving highly efficacious vaccines. The importance of AMA1 as a target of acquired human inhibitory antibodies, their allele specificity and prevalence in populations is unknown, but crucial for vaccine design. A major challenge in the development of highly efficacious vaccines is antigen polymorphism, which is an important issue for many leading vaccine candidates This includes the RTS,S vaccine, which recently completed phase III trials, and vaccines based on apical membrane antigen 1 (AMA1) and merozoite surface protein 2 (MSP2); for all these candidates, vaccine efficacy against malaria or Plasmodium falciparum infection was higher for episodes caused by vaccine-like strains compared to vaccine-dissimilar strains [1,2,3]. Knowledge on the distribution and prevalence in populations of functional immune responses to different alleles or strains for polymorphic vaccine candidates is very limited, but would be highly valuable for guiding vaccine design. The major targets of acquired invasion-inhibitory antibodies are unclear

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call